All studies
Phase 3RecruitingInterventionalNCT05519085

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

  • Relapsed or Refractory Multiple Myeloma
I want to take partRefer a patient8 sites in India (6 recruiting) · 266 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Celgene
Enrolment target
810
Started
20 September 2022
Main results due (estimated)
10 January 2027
Study ends (estimated)
30 November 2033
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
None
Sites
266 · 8 in India
First posted
29 August 2022
Registry updated
30 October 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria

\- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.

i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.

ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).

iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.

* Participants received 1 to 3 prior lines of antimyeloma therapy.
* Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.

Exclusion Criteria

\- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:.

i) Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded.

ii) Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded.

* For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
* Participant has had prior treatment with mezigdomide or pomalidomide.
* Other protocol-defined Inclusion/Exclusion criteria apply.

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Keywords: Multiple myeloma · RRMM · MeziVd · PVd · CC92480 · pomalidomide · bortezomib · dexamethasone · mezigdomide

What participants receive

  • Experimental

    MeziVd (mezigdomide, bortezomib and dexamethasone)

    Drug: mezigdomide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental

    PVd (pomalidomide, bortezomib and dexamethasone)

    Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • mezigdomideDrug

    Also known as BMS-986348, CC-92480

    Specified dose on specified days

  • PomalidomideDrug

    Also known as Pomalyst, Imnovid, Pom

    Specified dose on specified days

  • BortezomibDrug

    Also known as Velcade, BTZ

    Specified dose on specified days

  • DexamethasoneDrug

    Also known as Decadron, Dex

    Specified dose on specified days

What the study measures

Primary outcomes

  1. Progression-free Survival (PFS)

    Time frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)

Secondary outcomes

  1. Recommended mezigdomide dose

    Stage 1 only

    Time frame: Up to 12 Months

  2. Plasma concentrations of mezigdomide

    Stage 1 only

    Time frame: Up to 134 Days

  3. Overall Survival (OS)

    Time frame: From date of randomization to date of death due to any cause (Up to approximately 5 years)

  4. Overall Response (OR)

    OR is defined as the number of participants who achieve best response of partial response (PR) or better according to the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma

    Time frame: Up to approximately 5 years

  5. Complete Response (CR) or better

    Defined as the number of participants who achieve best response of complete response (CR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

    Time frame: Up to approximately 5 Years

  6. Very Good Partial Response (VGPR) or better

    Defined as the number of participants who achieve best response of very good partial response (VGPR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

    Time frame: Up to approximately 5 years

  7. Time to Response (TTR)

    Time frame: Up to approximately 5 years

  8. Duration of Response (DOR)

    Time frame: Up to approximately 5 years

  9. Time to Progression (TTP)

    Time frame: Up to approximately 5 years

  10. Time to Next Treatment (TTNT)

    Time frame: Up to approximately 5 years

  11. Progression-free Survival 2 (PFS-2)

    Time frame: Up to approximately 5 years

  12. Minimal Residual Disease (MRD) negativity

    Defined as the number of participants who achieve complete response (CR) or better and MRD negativity (defined as less than 1 in 10\^5 nucleated cells \[by next generation flow cytometry\] in bone marrow aspirate)

    Time frame: Up to approximately 5 years

  13. Number of participants with Adverse Events (AEs)

    Time frame: Up to approximately 5 years

  14. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores

    The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

    Time frame: Up to approximately 5 years

  15. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score

    The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

    Time frame: Up to approximately 5 years

Who is running it

Lead sponsor
Celgene
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Celgene
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
CA057-001
Other IDs
2023-509859-13, 2023
  • Bristol-Myers Squibb

    Study director

    Bristol-Myers Squibb

Study sites(266)

  • HCG Aastha Cancer Centre

    Ahmedabad, Gujarat, India

    Recruiting

  • Marengo Asia Hospitals Gurugram

    Gurugram, Haryana, India

    Recruiting

  • KLES Dr. Prabhakar Kore Hospital & M.R.C

    Belagavi, Karnataka, India

    Recruiting

  • Mumbai Oncocare Centre - Nanachowk

    Mumbai, Maharashtra, India

    Recruiting

  • Christian Medical College & Hospital

    Ludhiana, India

    Recruiting

  • Jawaharlal Institute Of Postgraduate Medical Education And Research

    Puducherry, India

    Recruiting

  • Local Institution - 0344

    Madurai, Tamil Nadu, India

    Completed

  • Local Institution - 0341

    Varanasi, Uttar Pradesh, India

    Completed

  • TUM Klinikum

    München, Bavaria, Germany

    Recruiting

  • Klinikum Traunstein

    Traunstein, Bavaria, Germany

    Recruiting

  • Medizinisches Versorgungszentrum

    Weiden, Bavaria, Germany

    Recruiting

  • Universitaetsklinik Marburg

    Marburg, Hesse, Germany

    Recruiting

  • Praxis Onkologie am Raschplatz

    Hanover, Lower Saxony, Germany

    Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany

    Recruiting

  • Marien Hospital Düsseldorf

    Düsseldorf, North Rhine-Westphalia, Germany

    Recruiting

  • Universitaetsklinikum Schleswig-Holstein Campus Kiel

    Kiel, Schleswig-Holstein, Germany

    Recruiting

  • Universitätsklinikum Aachen

    Aachen, Germany

    Recruiting

  • Sozialstiftung Bamberg

    Bamberg, Germany

    Recruiting

  • Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf

    Dresden, Germany

    Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

    Recruiting

  • Asklepios Altona

    Hamburg, Germany

    Recruiting

  • Universitaetsklinikum Tuebingen

    Tübingen, Germany

    Recruiting

  • Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher

    Würzburg, Germany

    Recruiting

  • G. Papanikolaou General Hospital

    Thessaloniki, Thessaloníki, Greece

    Recruiting

  • Hospital de Braga

    Braga, Portugal

    Recruiting

  • Champalimaud Foundation

    Lisbon, Portugal

    Recruiting

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE

    Porto, Portugal

    Recruiting

  • Pusan National University Hospital

    Busan, Busan, South Korea

    Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, Gyeonggido, South Korea

    Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeonranamdo, South Korea

    Recruiting

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

    Recruiting

  • Samsung Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea

    Recruiting

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

    Recruiting

  • Asan Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], South Korea

    Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

    Recruiting

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, United Kingdom

    Recruiting

  • The Royal Cornwall Hospital

    Truro, England, United Kingdom

    Recruiting

  • King's College Hospital

    London, Greater London, United Kingdom

    Recruiting

  • Lanarkshire NHS Trust - Monklands Hospital

    Airdrie, Lanarkshire, United Kingdom

    Recruiting

  • Leicester Royal Infirmary

    Leicester, Leicestershire, United Kingdom

    Recruiting

Showing 40 of 266 sites. 42 recruiting, 200 not recruiting and 24 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap, Csr
When
See Plan Description
Access
See Plan Description

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Source: ClinicalTrials.gov record NCT05519085, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.